In a challenging year marked by setbacks, Moderna continues to advance its research in cancer therapies. The company announced on March 15, 2025, that its experimental...
Novartis is seeking to advance the use of its radiopharmaceutical, Pluvicto, in the treatment of prostate cancer, aiming for its application in earlier stages of the...
Moderna, Inc. has announced promising early results from its investigational cancer therapy, mRNA-4359. This data will be presented at the 2025 European Society for Medical Oncology...
